Table 3.
Effect of inulin supplementation on liver function, bacterial translocation, and inflammatory markers in the global sample.
| Placebo n = 22 | Inulin n = 22 | Adjusted difference at T2 (inulin vs placebo) β [95% CI] | P1 | |
|---|---|---|---|---|
| T2 | T2 | |||
| Liver related markers (normal range) | ||||
| AST (<40 IU/L) | 24.9 ± 7.4 | 31.6 ± 17.7 | 8.55 [2.33; 14.77] | 0.008 |
| ALT (<40 IU/L) | 12.2 ± 6.8 | 16.6 ± 12.8 | 6.01 [2.02; 10.00] | 0.004 |
| CAP (< 250 dB/m) | 226.4 ± 39.5 | 243.9 ± 57.3 | 4.76 [-23.98; 33.51] | 0.73 |
| K18-M-65 (<270 pg/ml) | 221.1 ± 109.7 | 306.9 ± 204.9 | 74.48 [-1.89; 150.84] | 0.06 |
| FGF-21, pg/ml | 2240.2 ± 1409.9 | 2590.3 ± 1515.7 | -164.70 [-867.38; 537.97] | 0.64 |
| Bacterial translocation | ||||
| LBP, ng/ml | 18.7 ± 1.6 | 19.1 ± 1.7 | 0.46 [-0.30; 1.22] | 0.23 |
| sCD14, ng/ml | 1406.8 ± 282.2 | 1647.8 ± 448.7 | 94.71 [-92.61; 282.04] | 0.31 |
| PGRP, ng/ml | 50.2 ± 18.5 | 58.9 ± 24.7 | 2.39 [-7.61; 12.40] | 0.63 |
| Inflammation | ||||
| IL-18, pg/ml | 474.4 ± 208.4 | 545.3 ± 239.5 | 102.85 [15.46; 190.25] | 0.02 |
| IL-8, pg/ml | 5.3 ± 2.2 | 5.5 ± 2.2 | 0.22 [-1.09; 1.53] | 0.73 |
| MCP-1, pg/ml | 249.1 ± 81.8 | 240.0 ± 87.5 | -2.71 [-47.15; 41.7] | 0.90 |
| TNFα, pg/ml | 2.5 ± 1.2 | 3.1 ± 1.5 | 0.20 [-0.41; 0.80] | 0.51 |
| IL-6, pg/ml | 4.7 ± 2.7 | 4.7 ± 2.9 | -0.31 [-1.90; 1.27] | 0.69 |
| IL-10, pg/ml | 1.8 ± 1.1 | 1.9 ± 1.0 | -0.03 [-0.59; 0.53] | 0.92 |
1
Linear regression model adjusted for gender, the baseline measurement of the outcome and the quantity of ethanol consumed during the second week of the program
AST, Aspartate transaminase; ALT, Alanine transaminase; CAP, controlled attenuation parameter; FGF-21, Fibroblast growth factor 21; K18-M65, Serum keratin 18; sCD14, soluble CD14.